Akers Biosciences, Inc. AKER Income Statement

Akers biosciences, inc. (AKER)

Income statement / Quarterly

Mar'20	Dec'19	Sep'19	Jun'19	Mar'19	Dec'18	Sep'18	Jun'18	Mar'18	Dec'17	Sep'17	Jun'17	Mar'17	Dec'16	Sep'16	Jun'16	Mar'16	Dec'15	Sep'15	Jun'15	Mar'15	Dec'14	Sep'14	Jun'14	Mar'14	Dec'13	Sep'13	Jun'13	Mar'13
Product Revenue
363	79	420	464	612	279	557	526	302	-	675	1,072	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Product Revenue
-	-	-	-	-	-	-	-	-	-	-	-	-	649	613	956	737	432	169	744	411	1,363	359	405	324	320	261	361	382
Product Revenue
-	-	-	-	-	-	-	-	-	-	-	-	643	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Product Revenue - Related party
-	-	-	-	-	-	-	-	-	-	-	-	24	0	0	0	0	-	-	0	-	0	0	864	766	168	0	631	919
License & Service Revenue
-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-10	0	10	15	0	10	0	0	0	0	0	200
License Revenue - Related party
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	10	0	212	83	83	83	83	83	83	83	83	83
Total Revenues
-	-	-	-	-	-	-	-	-	-	-	-	667	653	613	956	738	468	169	966	510	1,446	453	1,353	1,173	571	344	1,076	1,585
Product Cost of Sales
172	346	285	219	245	461	476	302	297	1,533	323	290	258	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Product Cost of Sales
-	-	-	-	-	-	-	-	-	-	-	-	-	369	236	276	200	205	177	341	226	267	162	141	604	410	94	633	776
Gross Income
190	-267	135	244	366	-182	80	223	4	-594	352	782	408	283	376	679	537	263	-8	625	283	1,179	291	1,211	569	160	250	443	809
Sales and Marketing Expenses - Related Party
-	-	-	-	-	-	-	-	-	-	34	61	32	35	117	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Sales and Marketing Expenses - Related party
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	864	-	0	0	0	195	134	100	109	83
Research and Development Expenses
2,483	-	57	60	-	203	160	259	439	330	290	290	348	256	247	321	363	403	319	378	305	229	183	248	253	250	233	274	247
Administrative Expenses
1,157	869	895	981	982	1,478	1,706	1,565	915	1,642	819	829	790	710	558	816	923	1,688	760	882	698	1,481	826	1,017	458	343	270	271	210
Administrative Expenses - Related Party
-	-	-	-	-	-	-	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Sales and Marketing Expenses
14	35	38	14	149	448	364	469	500	794	342	354	556	336	408	513	725	688	725	553	575	335	358	396	211	148	126	176	233
Regulatory and Compliance Expenses
72	-	-	-	88	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Research and Development Expenses - Related Party
-	-	-	-	-	-	-	-	-	-	0	22	0	-	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-
Litigation Settlement Expenses
-	66	0	0	75	-	930	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
(Reversal of Allowance for) Bad Debt Expenses- Related parties
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-1,299	-	-	-	0	-	-	-	-	-	-	-	-	-	-
Impairment of Non-Current Assets
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	466	-	-	-	0	-	-	-	-	-	-
Amortization of Non-Current Assets
8	10	10	10	10	42	42	42	42	42	42	42	42	42	42	42	42	42	64	64	64	64	64	64	64	64	64	64	64
Loss from Operations
-3,545	-1,318	-865	-821	-940	-2,929	-3,124	-2,113	-1,893	-3,253	-1,177	-820	-1,362	-1,098	301	-1,014	-1,516	-3,859	-2,345	-2,117	-1,360	-932	-1,142	-515	-613	-780	-545	-452	-31
Other (Income) Expenses
Impairment of Non-Current Assets
2	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Gain on sale of equity investment - Related party
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	99	-
Foreign Currency Transaction Loss
-	0	-0	0	4	1	-0	3	2	4	3	0	-10	-5	3	2	2	-0	2	6	-0	-4	1	-1	2	-0	0	0	-0
Other Income
-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	-0	-0	-5	-	-	-	-	-	-	-	-
Other Income
-	-	-	-	-	-	4	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	0	0	0	-	0	91	-
Loss on Investments
36	-1	-6	0	3	-	6	4	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Gain from demutualization of insurance carrier
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-9	0	0	4	0	0	0	91
Interest and Dividend Income
46	20	22	27	31	33	42	53	36	1	3	3	2	18	5	8	-10	-12	-20	-37	-32	-41	-19	-19	10	0	0	0	1
Total Other Income
-7	20	-28	-26	-23	908	-40	-45	-33	767	0	-2	-12	30	8	-5	-8	-13	-18	-30	-38	-55	-18	-20	17	-0	0	191	92
Loss Before Income Taxes
-3,538	-1,339	-837	-794	-916	-3,837	-3,083	-2,067	-1,859	-4,021	-1,177	-818	-1,349	-1,095	310	-1,008	-1,508	-3,846	-2,326	-2,086	-1,321	-912	-1,124	-494	-595	-781	-544	-261	60
Income Tax Benefit
-	-	-	-	-	-	-	-	-	-	0	0	0	0	0	0	0	-269	0	0	0	0	0	0	0	0	0	0	0
Preferred Stock Dividend
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-15	-	-	0	0	-
Net Loss
-3,538	-1,339	-837	-794	-916	-3,837	-3,083	-2,067	-1,859	-4,021	-1,177	-818	-1,349	-1,095	310	-1,008	-1,508	-3,576	-2,326	-2,086	-1,321	-912	-1,124	-510	-595	-	-	-	60
Other Comprehensive Income (Loss)
Net Loss Attributable to Common Stockholders
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-544	-261	-
Net Unrealized Loss on Marketable Securities
-	-	-	-	-	-	-	-	-	-	-1	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net Unrealized Gain (Loss) on Marketable Securities
-240	-1	-1	18	29	-20	6	4	-16	-	-	-	0	2	-2	-2	8	-17	8	-3	26	-8	-8	7	-10	0	0	0	0
Total Other Comprehensive Income (Loss)
-240	-1	-1	18	29	-20	6	4	-16	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Comprehensive Loss
-3,779	-1,341	-838	-776	-887	-3,858	-3,077	-2,063	-1,876	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Other Comprehensive Loss
-	-	-	-	-	-	-	-	-	-	-1	0	0	2	-2	-2	8	-17	8	-3	26	-8	-8	7	-10	0	0	0	0
Comprehensive Loss
-	-	-	-	-	-	-	-	-	-4,021	-1,178	-817	-1,349	-1,093	307	-1,010	-1,500	-3,594	-2,318	-2,089	-1,295	-920	-1,132	-503	-606	-781	-544	-261	60
Basic income/(loss) per common share
-	-	-	-	-	-	-	-	-	-	-	-	-	-	0.06	-	-	-	-0.45	-	-	-	-	-	-	-	-	-	-
Diluted income/(loss) per common share
-	-	-	-	-	-	-	-	-	-	-	-	-	-	0.06	-	-	-	-0.45	-	-	-	-	-	-	-	-	-	-
Weighted average basic common shares outstanding
-	-	-	-	-	-	-	-	-	-	-	-	-	-	5,434	-	-	-	5,144	-	-	-	-	-	-	-	-	-	-
Weighted average diluted common shares outstanding
-	-	-	-	-	-	-	-	-	-	-	-	-	-	5,508	-	-	-	5,144	-	-	-	-	-	-	-	-	-	-
Basic and Diluted loss per common share
-1.59	-4.52	-0.07	-0.06	-1.70	-21.63	-0.26	-0.18	-0.21	-4.97	-1.04	-0.09	-0.19	-	-	-0.19	-0.28	-	-	-0.41	-0.26	-0.19	-0.23	-0.10	-0.14	-0.52	-0.30	-0.19	0.05
Weighted average basic and diluted common shares outstanding
2,226	-23,103	12,512	12,500	540	-30,444	11,779	11,656	8,956	-12,300	1,111	8,882	6,993	-	-	5,427	5,425	-	-	5,144	5,125	4,965	4,924	4,894	4,197	1,947	1,791	1,369	1,278